Foundation news
Facio Therapies announced today that it has selected its first series of potential FSHD drug development candidates. This series comprises several families of small-molecule compounds that are associated with a narrowly defined target class. Neither the compound families nor the target class have ever been linked to FSHD in the scientific literature.
Article originally appeared on sciencedaily.com, November 7, 2017. In a recent paper published in the journal Skeletal Muscle, a Saint Louis University researcher reports success in identifying new drug targets that potentially could slow or halt the progression of a form muscular dystrophy, an illness characterized by progressive muscle degeneration. Francis M. Sverdrup, Ph.D., research fellow in the …
Read more “FSHD NEWS: New drug targets for a form of muscular dystrophy”
Article originally appeared on musculardystrophynews.com, October 10, 2017. Resolaris (ATYR1940) improved the muscle strength of nearly two-thirds of adolescents and young adults with early-onset facioscapulohumeral muscular dystrophy (FSHD), according to final results of a Phase 1/2 clinical trial. The therapy’s maker, aTyr Pharma, presented the findings at the 22nd International Annual Congress of the World Muscle Society (WMS) in Saint Malo, France, according to a press release. The …
Bruce Beck of NBC 4 provides coverage of the C2C4FSHD bike tour.
Frank Carbone’s energy is infectious. Starting in Seattle and for the better part of two months, he led a group of cyclists across the country. CBS2’s Steve Overmyer caught up with him during a two-minute pit stop in Fort Lee before entering their final leg through New York City. “We’re home!” Carbone said. “Fifty-four days on the road!”
A 4,200-mile journey through 15 states that began in Seattle in May came to an end in Brooklyn Wednesday afternoon, as cyclists pedaled their way to the Barclays Center and celebrated the funding and awareness they raised for facioscapulohumeral muscular dystrophy.
Post by Chris Carrino June 20th is World FSHD Day. A day of awareness for FSHD, to show we are united for a cure. However, for those of us affected by this disease, June 20th is simply known as – Tuesday. There isn’t a moment of every day that I’m not acutely aware …
Fastfoward to the 18:45 minute mark to hear Chris’ interview.
This article originally appeared on app.com Jerry Carino , @njhoopshaven Published 5:02 a.m. ET May 18, 2017 | Updated 4:20 p.m. ET May 20, 2017 As the new co-director of a highly successful sports broadcasting camp for teens, Marlboro’s Chris Carrino draws on experiences beyond the basketball court. A few years …
This story was originally published on musculardystrophynews.com on April 27, 2017. Resolaris, a protein therapy developed for rare muscle diseases by aTyr Pharma, improved muscle strength and quality of life in a small study of patients with early onset facioscapulohumeral muscular dystrophy (FSHD). These findings, as well as others regarding the effect of Resolaris in patients with …